Journal of Clinical Oncology
Articles in this Issue
Impact and validation of the Clavien-Dindo classification for oncologic surgeries in a high-volume center in Latin America: A single-center retrospective study.
e23249 Background: Although the Clavien-Dindo classification (CDC) has emerged as a tool for postsurgical complication assessment, its application in Lati...
Impact of obesity and lifestyle-associated risk factors on outcomes of early-onset colorectal cancer in patients younger than 50 years old: A propensity-matched analysis.
3582 Background: Early-onset colorectal cancer (CRC) incidence is rising in individuals under 50 years old. This study aims to understand the factors infl...
Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.
1074 Background: The Cyclin Dependent Kinase 4/6 inhibitors (CDK4/6i) Palbociclib (P), Ribociclib (R) and Abemaciclib (A) combined with Endocrine Therapy...
Effect of a novel compound that covalently binds to the HPV16 E6 protein on proliferation of HPV-associated cervical and oropharyngeal cancer cells through p53 effector pathway activation.
e15103 Background: The human papillomavirus (HPV) E6 protein is always expressed in HPV-induced malignancies. We identified compounds that specifically bi...
MOLGEN: Detecting new DPYD variants for the safer delivery of 5FU and capecitabine.
12120 Background: Adverse drug reactions (ADRs) pose a significant challenge to healthcare systems, leading to 6.5-15% of NHS hospital admissions costing...
Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center.
e20653 Background: FLAURA2 demonstrated that adding chemotherapy to osimertinib improved progression-free survival compared to osimertinib monotherapy in...
Trends in inflation-adjusted costs and reimbursements for breast cancer procedures: A decade of decline.
e23131 Background: As healthcare costs continue to rise, understanding trends in reimbursement for breast cancer surgical procedures is crucial for both p...
EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.
5573 Background: A predictor of response to anti-PD1 therapy is the extent of CD8+ infiltration within the pretreated tumor. TIGIT has shown to suppress a...
Comparative analysis of T-cell subsets and vessel features in matched primary colorectal tumors and corresponding resected liver metastases.
3139 Background: Outcome after liver resection for colorectal cancer metastases (CRLM) is partly determined by factors such as the number, size, and vital...
Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in <i>KRAS</i> G12C-mutant advanced colorectal cancer.
3507 Background: Olomorasib, a potent and selective second-generation KRAS G12C inhibitor (G12Ci), has demonstrated promis...
CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study.
7013 Background: Patients (pts) with transplant-ineligible r/r DLBCL have an unmet need, with an objective response rate (ORR) of around 40%. CD79b, a key...
Epidemiologic trends in colorectal cancer: Age-related variations and site-specific patterns over two decades.
e15678 Background: Colorectal cancer (CRC) is the 2nd most common cause of cancer related death in the United States (1). While the incidence of CRC in th...
A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors.
1027 Background: BAT8010 is an ADC argeting HER2, while BAT1006 is a humanized monoclonal antibody targeting another epitope of HER2, with ADCC enhancemen...
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.
5047 Background: In the China cohort of the TALAPRO-2 study, unselected pts with mCRPC who received TALA + ENZA had improved radiographic progression-free...
Test performance of a DNA methylation–based liquid biopsy biomarker for detection and classification of pleural mesothelioma (PM).
8082 Background: Circulating tumor DNA (ctDNA) profiling in pleural mesothelioma (PM) is challenging due to its molecular heterogeneity and lack of mesoth...
Free flap surgery for oral squamous cell carcinoma: Postoperative complications and its association with oncologic outcomes.
e18096 Background: Surgical resection with free flap reconstruction is a cornerstone in the management of oral cavity squamous cell carcinoma (OCSCC). Thi...
Safety and tolerability of olaparib, temozolomide, and pembrolizumab in a phase 2 trial in patients with progressive glioblastoma.
2055 Background: Glioblastoma is the most aggressive primary brain tumor of adults, with patients obtaining limited survival benefit from standard-of-care...
Risk factors and clinicopathological features of young women with breast cancer: An observational study.
e13114 Background: Breast cancer in young women presents as an aggressive disease with advanced clinical stages and worse prognosis. Understanding the inf...
Efficacy and safety of stereotactic body radiotherapy vs. conventional radiotherapy for early-stage non-small cell lung cancer: A systematic review.
e20079 Background: Stereotactic body radiotherapy (SBRT) has gained widespread acceptance as a treatment modality for medically inoperable early-stage non...
Prostate specific antigen (PSA) screening from fingerstick blood: Initial validation of a point-of-care (POC) test.
e17164 Background: Prostate cancer (PC) is the most common cancer among men in the U.S. Compared to Caucasians, Black men have a higher PC incidence, are...
Self-reported adherence to cancer therapy: Development and validation of a cancer-specific DOSE-Nonadherence measure.
11106 Background: Patients with cancer take different types of medication (e.g., enteral, parenteral), with varying treatment schedules, in various settin...
Real-world adherence and tolerability of FLT3 inhibitors as post-allogeneic transplant maintenance therapy in older adults with AML: A Medicare claims data cohort study.
e18505 Background: The use of allogeneic hematopoietic cell transplantation (alloHCT) is increasing in older adults with acute myeloid leukemia (AML). Alt...
Comparative analysis of adverse event profiles for CAR-T cell therapies and bispecific antibodies in lymphoma.
e19019 Background: CAR-T cell therapies and bispecific antibodies (BsAbs) emerged as transformative treatment options for relapsed or refractory lymphomas...
Genetics and family history in a diverse cohort of females with early-onset breast cancer.
10613 Background: Genetic testing for breast cancer susceptibility genes is a crucial component of clinical care for patients with early-onset breast canc...
Prevalence of obesity/overweight and its relationship with incidence of pancreatic cancer in the US states using BRFSS and CDC WONDER database of 2021.
e22573 Background: Pancreatic cancer (PC) is a leading cause of cancer-related deaths, with a higher incidence in the US compared to other countries. Prev...